We help discover multi-biomarker panels which are
more robust, highly specific and sensitive


Our proprietary algorithms and pipelines
allow us to deliver unique multi-biomarker panels


Machine learning, evolutionary algorithms and
fuzzy logic are changing the face of
multi-biomarker panels discovery

The truth is in your data. We help find it!

Imagine providing multi-type and unbalanced data sets and discovering multi-biomarker panels in 48 hours, even with missing data. SimplicityBio makes this possible today! Answer your production, regulatory and IP requirements with robust, highly specific and sensitive multi-biomarker panels.

Why multiple biomarkers?

The advantages of a multi-biomarker approach in comparison to a single biomarker one are based on the premise that the single-valued index, with its aggregated information from complementary biomarkers, will outperform each of its component biomarkers used individually.

Multi-biomarker panels approach

We develop combinations of panels to produce a final panel. This "modular redundancy" approach allows the correction and/or compensation of a model that is not deemed efficient by other models; thereby it improves considerably the reliability of the final answer.

How do we do it?

We are able to test billions of hypotheses and biomarker combinations in order to find the most accurate and robust panels. These biomarkers are selected in our high performance software platform for in-silico multi-biomarker panel discovery.

Our Clients


BIO Europe Cologne 2016

SimplicityBio was selected by Johnson & Johnson Innovation to present at BIO Europe. Drop by or schedule a 1-to-1 meeting. Cologne, Germany. November 7-9, 2016.

Swiss Startup Day 2016

SimplicityBio was selected to pitch in front of investors at the Swiss Startup Day. Drop by or schedule a 1-to-1 meeting. Bern, Switzerland. October 25, 2016.

Swiss Patent Pending

SimplicityBio has a Swiss Patent Pending on its technology and methods. For more information please contact us.

Client publication in Cancer Research

Our client Cellipse has published a peer-reviewed article in AACR’s “The Journal of Cancer Research”, 1 June 2016 Edition.